REVIVA PHARMACEUTICALS HOLDI (RVPH)
US76152G1004 - Common Stock
Overall RVPH gets a fundamental rating of 0 out of 10. We evaluated RVPH against 193 industry peers in the Pharmaceuticals industry. RVPH has a bad profitability rating. Also its financial health evaluation is rather negative. RVPH has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
RVPH had negative earnings in the past year.
In the past year RVPH has reported a negative cash flow from operations.
In multiple years RVPH reported negative net income over the last 5 years.
RVPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RVPH's Return On Assets of -437.54% is on the low side compared to the rest of the industry. RVPH is outperformed by 95.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -437.54% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-51.59%
ROA(5y)N/A
ROE(3y)-75.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RVPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVPH has more shares outstanding than it did 1 year ago.
RVPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -44.08, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
RVPH has a Altman-Z score of -44.08. This is amonst the worse of the industry: RVPH underperforms 93.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -44.08 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
RVPH has a Current Ratio of 0.39. This is a bad value and indicates that RVPH is not financially healthy enough and could expect problems in meeting its short term obligations.
RVPH has a worse Current ratio (0.39) than 96.86% of its industry peers.
RVPH has a Quick Ratio of 0.39. This is a bad value and indicates that RVPH is not financially healthy enough and could expect problems in meeting its short term obligations.
RVPH has a Quick ratio of 0.39. This is amonst the worse of the industry: RVPH underperforms 96.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.39 | ||
| Quick Ratio | 0.39 |
3. Growth
3.1 Past
RVPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.53%, which is quite impressive.
EPS 1Y (TTM)33.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 10.63% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.01%
EPS Next 2Y10.73%
EPS Next 3Y9.2%
EPS Next 5Y10.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RVPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y9.2%
5. Dividend
5.1 Amount
No dividends for RVPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REVIVA PHARMACEUTICALS HOLDI
NASDAQ:RVPH (12/20/2024, 8:00:01 PM)
After market: 1.36 +0.02 (+1.49%)1.34
-0.16 (-10.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.67%
Inst Owner Change47.02%
Ins Owners10.62%
Ins Owner Change0%
Market Cap44.81M
Analysts80
Price Target15.5 (1056.72%)
Short Float %21.62%
Short Ratio3.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.23%
Min EPS beat(2)0.37%
Max EPS beat(2)12.1%
EPS beat(4)4
Avg EPS beat(4)12.51%
Min EPS beat(4)0.37%
Max EPS beat(4)34.93%
EPS beat(8)5
Avg EPS beat(8)-15.38%
EPS beat(12)8
Avg EPS beat(12)-7.68%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.33%
EPS NQ rev (1m)0.71%
EPS NQ rev (3m)19.42%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS-0.3
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -437.54% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-51.59%
ROA(5y)N/A
ROE(3y)-75.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.39 | ||
| Quick Ratio | 0.39 | ||
| Altman-Z | -44.08 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.18%
EPS Next Y-33.01%
EPS Next 2Y10.73%
EPS Next 3Y9.2%
EPS Next 5Y10.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-226.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-226.99%
OCF growth 3YN/A
OCF growth 5YN/A